(CNN) Results from a study investigating Gilead Sciences' antiviral medication remdesivir as a Covid-19 treatment were posted to the World Health Organization's website "prematurely" on Thursday and showed "inconclusive" results, according to the biotechnology company.

The information is no longer on WHO's website.

"Today, information from the first clinical study evaluating the investigational antiviral remdesivir in patients with severe Covid-19 disease in China was prematurely posted on the World Health Organization website. This information has since been removed, as the study investigators did not provide permission for the publication of the results. Furthermore, we believe the post included inappropriate characterizations of the study," said Dr. Merdad Parsey, chief medical officer of Gilead Sciences in a statement on Twitter

Gilead statement on data from study in patients with severe COVID-19 in China: https://t.co/pDsnSmVijG. pic.twitter.com/UpqR5EJqvQ — Gilead Sciences (@GileadSciences) April 23, 2020

"The study was terminated early due to low enrollment and, as a result, it was underpowered to enable statistically meaningful conclusions," the tweet said. "As such, the study results are inconclusive, though trends in the data suggest a potential benefit for remdesivir, particularly among patients treated early in disease. We understand the available data have been submitted for peer-reviewed publication, which will provide more detailed information from this study in the near future."

A screenshot of the study description posted to WHO's website was published by STAT on Thursday. The description in the screenshot notes that the study, which involved 237 patients, found "remdesivir use was not associated with a difference in time to clinical improvement" and "in this study of hospitalized adult patients with severe Covid-19 that was terminated prematurely, remdesivir was not associated with clinical or virological benefits."

Read More